Emerging themes in medicinal glycoscience

Nature Biotechnology

Volumn 18, Issue 8, 2000, Pages 835-841

  Koeller, K M ^a   Wong, C H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Antibiotic; Glycoconjugate; Synthesis; Therapeutic; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; CARBOHYDRATE; GLYCOCONJUGATE; VACCINE;

DRUG ACTIVITY; DRUG DESIGN; DRUG SYNTHESIS; IMMUNE SYSTEM; MOLECULAR RECOGNITION; PRIORITY JOURNAL; REVIEW; VIRUS INHIBITION;

ANTI-INFECTIVE AGENTS; CARBOHYDRATE SEQUENCE; GLYCOCONJUGATES; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 0033897809     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/78435     Document Type: Review

References (103)

1. Biological roles of oligosaccharides: All of the theories are correct
2. Glycobiology: Toward understanding the function of sugars
3. Enzyme action in glycoprotein synthesis
4. Carbohydrate mimetics: A new strategy for tackling the problem of carbohydrate-mediated biological recognition
5. Glycosylation inhibitors in biology and medicine
6. Selectins and their ligands: Current concepts and controversies
7. Glycosphingolipid antigens and cancer therapy
8. Chemistry, biology, and medicine of the glycopeptide antibiotics
9. Heparinoid mimetics
10. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors
11. Cell surface carbohydrates: Cell-type specific expression
12. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins
13. Survival of recombinant erythropoeitin in the circulation: The role of carbohydrates
14. Getting the glycosylation right: Implications for the biotechnology industry
15. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides
16. Enzymes in organic synthesis: Application to the problems of carbohydrate recognition (parts 1 and 2)
17. Recent advances in the chemoenzymatic synthesis of carbohydrates and carbohydrate mimetics
18. Synthesis of complex carbohydrates and glycoconjugates: Enzyme-based and programmable one-pot strategies
19. Enzymatic glycoprotein synthesis: Preparation of ribonuclease glycoforms via enzymatic glycopeptide condensation and glycosylation
20. Comparative lipase-catalyzed hydrolysis of ethylene glycol derived esters. The 2-methoxyethyl ester as a protective group in peptide and glycopeptide synthesis
21. 3 using subtilisin
22. The catalytic asymmetric aldol reaction
23. Enzymatic regeneration of 3'-phosphoadenosine-5'-phosphosulfate using aryl sulfotransferase for the preparative enzymatic synthesis of sulfated carbohydrates
24. Fmoc-based synthesis of peptide (α)thioesters: Application to the total chemical synthesis of a glycoprotein by native chemical ligation
25. Intein-mediated synthesis of proteins containing carbohydrates and other molecular probes
26. Combined chemical and enzymatic synthesis of a C-glycopeptide and its inhibitory activity toward glycoamidases
27. Programmable one-pot oligosaccharide synthesis
28. Taking aim at a moving target-inhibitors of influenza virus part 1: Virus adsorption, entry, and uncoating
29. Taking aim at a moving target-inhibitors of influenza virus part 2: Viral replication, packaging and release
30. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors
31. A lysoganglioside/poly-L-glutamic acid conjugate as a picomolar inhibitor of influenza hemagglutinin
32. Rational design of potent sialidase-based inhibitors of influenza virus replication
33. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity
34. Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide
35. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry
36. Carbon-linked galactosphingolipid analogs bind specifically to HIV-1 gp120
37. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production
38. Rapid combinatorial synthesis of aminoglycoside antibiotic mimetics: Use of a polyethylene glycol-linked amine and a neamine-derived aldehyde in multiple component condensation as a strategy for the discovery of new inhibitors of the HIV RNA Rev responsive element
39. Neomycin-acridine conjugate: A potent inhibitor of Rev-RRE binding
40. Microbial recognition of target-cell glycoconjugates
41. The vancomycin group of antibiotics and the fight against resistant bacteria
42. The roles of dimerization and membrane anchoring in activity of glycopeptide antibiotics against vancomycin-resistant bacteria
43. Combinatorial library approach for the identification of synthetic receptors targeting vancomycin-resistant bacteria
44. A trivalent system from vancomycin: D-Ala-D-Ala with higher affinity than avidin-biotin
45. Tight binding of a dimeric derivative of vancomycin with dimeric D-Ala-D-Ala
46. Novel vancomycin dimers with activity against vancomycin-resistant enterococci
47. Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala
48. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: Biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA
49. Bacterial resistance to vancomycin: Five genes and one missing hydrogen bond tell the story
50. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala
51. Combinatorial biosynthesis of erythromycin and complex polyketides
52. Harnessing the biosynthetic code: Combinations, permutations, and mutations
53. Endotoxin antagonists: Possible candidates for the treatment of gram-negative sepsis
54. E5531, a pure endotoxin antagonist of high potency
55. A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis
56. Antibacterial agents that target Lipid A biosynthesis in gram-negative bacteria
57. Inhibition of Helicobacter pylori binding to gastrointestinal epithelial cells by sialic acid-containing oligosaccharides
58. Attachment of Heliobacter pylori to human gastric epithelium mediated by blood group antigens
59. Solution- and solid-phase synthesis of inhibitors of H. pylori attachment and E-selectin-mediated leukocyte adhesion
60. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands
61. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness
62. Parasite and mammalian GPI biosynthetic pathways can be distinguished using synthetic substrate analogues
63. Specificity of amino-glycoside antibiotics for the A-site of the decoding region of ribosomal RNA
64. Interaction of antibiotics with functional sites in 16S ribosomal RNA
65. Prodigious substrate specificity of AAC(6')-APH(2''), an aminoglycoside antibiotic resistance determinant in enterococci and staphylococci
66. Design and synthesis of new aminoglycoside antibiotics containing neamine as an optimal core structure: Correlation of antibiotic activity with in vitro inhibition of translation
67. Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes
68. An antibiotic cloaked by its own resistance mechanism
69. RNA as a small-molecule drug target: Doubling the value of genomics
70. Design of small molecules that recognize RNA: Development of aminoglycosides as potential antitumor agents that target oncogenic RNA sequences
71. Enhanced inhibition of human anti-gal antibody binding to mammalian cells by synthetic α-gal epitope polymers
72. Capsular polysaccharide-protein conjugate vaccines
73. Bacterial polysaccharide-protein conjugate vaccines
74. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen
75. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells
76. 1-mediated immune responses to glycolipids
77. Polysialic acid engineering: Synthesis of polysialylated neoglycosphingolipids by using the polysialytransferase from neuroinvasive Escherichia coli K1
78. Expression of α2,8/2,9-polysialyltransferase from Escherichia coli K92
79. CD1d-restricted and TCR-mediated activation of V(α)14 NKT cells by glycosylceramides
80. From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines
81. A fully synthetic Globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle
82. Evidence of a cellular immune response against sialyl-T(n) in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with theratope ST(n)-KLH cancer vaccine
83. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses
84. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes
85. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin
86. A chemical concept for the treatment of Tay-Sachs disease
87. Sphingolipids - Their metabolic pathways and the patho-biochemistry of neurodegenerative diseases
88. Selectin-carbohydrate interactions: From natural ligands to designed mimetics
89. Synthetic ligands point to cell surface strategies
90. Synthesis of an RGD-sialyl-Lewis x glycoconjugate: A new highly active ligand for P-selectin
91. Glycopeptide and oligosaccharide libraries
92. Therapeutic effect of intradermal injections with difucosyl lactosamine (dimeric Le(x)) on patients with rheumatoid arthritis
93. Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein
94. First synthetic carbohydrates with the full anticoagulant properties of heparin
95. Synthesis of thrombin-inhibiting heparin mimetics without side effects
96. Use of recombinant human erythropoietin outside the setting of uremia
97. Glycoprotein pharmaceuticals: Scientific and regulatory considerations, and the US orphan drug act
98. Glycoprotein glycans - Roles and controls
99. Small peptides as potent mimetics of the protein hormone erythropoietin
100. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 Å
101. Enzymatic transfer of a preassembled trisaccharide antigen to cell surfaces using a fucosyltransferase
102. Engineering chemical reactivity on cell surfaces through oligosaccharide biosynthesis